These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1117 related items for PubMed ID: 27388275

  • 1. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F, Pedernera E, Reynaga-Obregón J, López-Basave HN, Gómora MJ, Carlón E, Cárdenas S, Silva-Ayala R, Almaraz M, Méndez C.
    J Ovarian Res; 2016 Jul 07; 9(1):41. PubMed ID: 27388275
    [Abstract] [Full Text] [Related]

  • 2. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
    Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, Mano Y, Yamamoto K, Nagata I.
    Gynecol Obstet Invest; 1999 Jul 07; 47(1):52-7. PubMed ID: 9852392
    [Abstract] [Full Text] [Related]

  • 3. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
    Pradjatmo H, Pradjatmo H.
    Asian Pac J Cancer Prev; 2016 Jul 07; 17(4):1881-6. PubMed ID: 27221870
    [Abstract] [Full Text] [Related]

  • 4. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP, Huang QD, Wan T, Tu H, Gu HF, Cao JY, Liu JH.
    J Ovarian Res; 2019 Jul 31; 12(1):72. PubMed ID: 31362750
    [Abstract] [Full Text] [Related]

  • 5. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
    Asali A, Haj-Yehia N, Zehavi T, Perry T, Beiner M, Fishman A, Kadan Y.
    J Obstet Gynaecol; 2021 Oct 31; 41(7):1107-1111. PubMed ID: 33427544
    [Abstract] [Full Text] [Related]

  • 6. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y, Li L.
    Tumour Biol; 2016 Nov 31; 37(11):14765-14772. PubMed ID: 27629144
    [Abstract] [Full Text] [Related]

  • 7. The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer.
    May T, Stewart JM, Bernardini MQ, Ferguson SE, Laframboise S, Jiang H, Rosen B.
    Int J Gynaecol Obstet; 2018 Feb 31; 140(2):247-252. PubMed ID: 29095487
    [Abstract] [Full Text] [Related]

  • 8. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL, Wang CJ, Qi P, Zhang YX.
    Clin Transl Oncol; 2017 Oct 31; 19(10):1260-1267. PubMed ID: 28444641
    [Abstract] [Full Text] [Related]

  • 9. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
    Shinagare AB, Balthazar P, Ip IK, Lacson R, Liu J, Ramaiya N, Khorasani R.
    J Am Coll Radiol; 2018 Aug 31; 15(8):1133-1138. PubMed ID: 29789232
    [Abstract] [Full Text] [Related]

  • 10. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
    Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A.
    Int J Gynecol Cancer; 2011 Aug 31; 21(6):1040-7. PubMed ID: 21738039
    [Abstract] [Full Text] [Related]

  • 11. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC, Zannoni GF, Tudisco R, Pasciuto T, Di Giorgio A, Franchi M, Scambia G, Fagotti A.
    Int J Gynecol Cancer; 2020 Jan 31; 30(1):67-73. PubMed ID: 31754067
    [Abstract] [Full Text] [Related]

  • 12. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
    Salminen L, Nadeem N, Jain S, Grènman S, Carpén O, Hietanen S, Oksa S, Lamminmäki U, Pettersson K, Gidwani K, Huhtinen K, Hynninen J.
    Gynecol Oncol; 2020 Mar 31; 156(3):689-694. PubMed ID: 31889528
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
    Tate S, Hirai Y, Takeshima N, Hasumi K.
    Gynecol Oncol; 2005 Jan 31; 96(1):143-9. PubMed ID: 15589593
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.
    Lancet Oncol; 2013 Aug 31; 14(9):853-62. PubMed ID: 23845225
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.